A View from Erika Jonietz

WHO Approves Smallpox Experiments

New Scientist is reporting that a World Health Organization committee has approved “in principal” experiments with live smallpox virus. The goal is to improve vaccines and drugs. Before any experiments proceed, the decision must be approved by the WHO’s member…

  • November 12, 2004

New Scientist is reporting that a World Health Organization committee has approved “in principal” experiments with live smallpox virus. The goal is to improve vaccines and drugs. Before any experiments proceed, the decision must be approved by the WHO’s member countries at an assembly in May 2005. In addition, each individual experiment would have to be reviewed by the same advisory committee and local biosafety authorities.

The WHO declared smallpox eradicated in 1980, and the only stockpiles were kept at the U.S. Centers for Disease Control and Prevention and at Vector, the Russian State Research Center for Virology. Any new smallpox outbreak would be due either to a lab accident or to a bioterror attack.

Other proposed experiments would insert smallpox genes into related viruses so that researchers could test drugs that target specific viral enzymes, helping to make sure a drug would work against the true smallpox enzyme. (Present treatment plans in case of an outbreak call for the use of antiviral drugs that have never been tested against smallpox.)

However, a leading expert has questioned the necessity of the tests. D.A. Henderson, who led the eradication drive and chairs the WHO’s committee on smallpox and related viruses, told New Scientist the research is “pointless.” His reasoning is pretty sound: any new drug or vaccine can’t be tested for efficacy in people, making them of dubious value. And, as Henderson points out, it’s unlikely anyone will spend the billions of dollars necessary to make and stockpile any of these new compounds. There’s a small chance the U.S. government could choose to spend that money. But if it does, it’s a clear case of stockpiling against a theoretical attack instead of spending money to help provide basic healthcare to millions of Americans in need.

Uh oh–you've read all of your free articles for this month.

Insider Premium
$179.95/yr US PRICE

Want more award-winning journalism? Subscribe to Insider Plus.
  • Insider Plus {! insider.prices.plus !}*

    {! insider.display.menuOptionsLabel !}

    Everything included in Insider Basic, plus ad-free web experience, select discounts to partner offerings and MIT Technology Review events

    See details+

    What's Included

    Bimonthly magazine delivery and unlimited 24/7 access to MIT Technology Review’s website

    The Download: our daily newsletter of what's important in technology and innovation

    Access to the magazine PDF archive—thousands of articles going back to 1899 at your fingertips

    Special discounts to select partner offerings

    Discount to MIT Technology Review events

    Ad-free web experience

/
You've read all of your free articles this month. This is your last free article this month. You've read of free articles this month. or  for unlimited online access.